title: Risk Factors for Adverse Outcomes in Patients Hospitalized With Lower Gastrointestinal Bleeding.
abstract: OBJECTIVE
  To determine which risk factors and subtypes of lower gastrointestinal bleeding (LGIB) are associated with adverse outcomes after hospital discharge (30-day readmissions, recurrent LGIB, and death).
  
  
  METHODS
  We conducted a prospective observational study of consecutive patients admitted with LGIB to Beth Israel Deaconess Medical Center from April 1, 2013, through March 30, 2014. Patients were contacted 30 days after discharge to determine hospital readmissions, recurrent LGIB, and death. Multivariable Cox proportional hazards regression models were used to describe associations of variables with 30-day readmissions or recurrent LGIB. Logistic regression was used to determine association with mortality.
  
  
  RESULTS
  There were 277 patients hospitalized with LGIB. Of the 271 patients surviving to discharge, 21% (n=57) were readmitted within 30 days, 21 of whom were admitted for recurrent LGIB. The following factors were associated with 30-day readmissions: developing in-hospital LGIB (hazard ratio [HR], 2.26; 95% CI, 1.08-4.28), anticoagulation (HR, 1.82; 95% CI, 1.05-3.10), and active malignancy (HR, 2.33; 95% CI, 1.11-4.42). Patients discharged while taking anticoagulants had higher rates of recurrent bleeding (HR, 2.93; 95% CI, 1.15-6.95). Patients with higher Charlson Comorbidity Index scores (odds ratio [OR], 1.57; 95% CI, 1.25-2.08), active malignancy (OR, 6.57; 95% CI, 1.28-28.7), and in-hospital LGIB (OR, 11.5; 95% CI, 2.56-52.0) had increased 30-day mortality risk.
  
  
  CONCLUSIONS
  In-hospital LGIB, anticoagulation, and active malignancy are risk factors for 30-day readmissions in patients hospitalized with LGIB. In-hospital LGIB, Charlson Comorbidity Index scores, and active malignancy are risk factors for 30-day mortality.
authors.affiliation: Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address: nsengup1@bidmc.harvard.edu.
authors.forename: Neil
authors.initials: N
authors.lastname: Sengupta
authors.affiliation: Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA.
authors.forename: Elliot B
authors.initials: EB
authors.lastname: Tapper
authors.affiliation: Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA.
authors.forename: Vilas R
authors.initials: VR
authors.lastname: Patwardhan
authors.affiliation: Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA.
authors.forename: Gyanprakash A
authors.initials: GA
authors.lastname: Ketwaroo
authors.affiliation: Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA.
authors.forename: Adarsh M
authors.initials: AM
authors.lastname: Thaker
authors.affiliation: Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Leffler
authors.affiliation: Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA.
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Feuerstein
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000175:diagnosis* / Q000401:mortality*; D006760:Hospitalization; D006801:Humans; D007410:Intestinal Diseases / Q000175:diagnosis* / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012008:Recurrence; D012307:Risk Factors
chemical_list: D000925:Anticoagulants